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INTRODUCTION
Transitional cell carcinoma of the upper urinary tract (TCC-
UUT) is a relatively uncommon disease, accounting for 4.5-
9% of all renal tumors and 5-6% of all urothelial tumors (1).
The incidence of TCC-UUT appears to have increased recent-
ly, probably due to increased environmental exposure and
aging population (2). The upper urinary tract has anatomi-
cal characteristics such as a thin muscle layer, proximity to
the kidney and rich lymphatic drainage. Tumor invasion may
significantly influence distant metastasis and progression in
patients with TCC-UUT (3). However, the exact molecular
mechanisms of tumor invasion, recurrence, progression, and
prognosis of this disease remain largely unclear.
Caveolins are the major structural proteins of caveolae, the
vesicular invaginations of the plasma membrane. The caveolin
family includes caveolin-1, -2, and -3. Caveolin-1 and -2 are
co-expressed in many cell types including adipocytes, endothe-
lial cells, smooth muscle cells, and fibroblasts, whereas the
expression of caveolin-3 is muscle-specific (4-6). Caveolin-1
has been implicated in intracellular transport, membrane
trafficking, and signal transduction (5), and has also been
shown to play an important role in various human patho-
logical conditions, including cancer, diabetes, bladder dys-
function, muscular dystrophy, and those related to the car-
diovascular system such as atherosclerosis, cardiac hypertro-
phy, cardiomyopathy, pulmonary hypertension, and neointi-
mal hyperplasia (6, 7).
The role of caveolin-1 in cancers remains controversial,
because caveolin-1 has been reported to be dysregulated in
various cancers, but the pattern of dysregulation appears to
vary with cancer types. The caveolin-1 expression is decreased
in several cancers such as ovarian carcinoma, pulmonary ade-
nocarcinoma, various soft tissue sarcomas, and breast cancer
and thought to function as a tumor suppressor gene (8-11).
On the other hand, the caveolin-1 expression is upregulated
in the other cancers such as renal cell carcinoma, prostate can-
cer, bladder cancer, colonic adenocarcinoma, and esophageal
squamous cell carcinoma and associated with higher stage,
cancer progression, and poor prognosis (12-17).
There have been no previous studies about caveolin-1 expres-
sion in TCC-UUT. In the present study, therefore, we inves-
tigated the relationship between caveolin-1 expression and
prognosis in patients with TCC-UUT.
MATERIALS AND METHODS
Patients and specimens
Formalin-fixed, paraffin-embedded, archival surgical speci-
mens that had been obtained from 98 patients (76 men and
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Impact of Caveolin-1 Expression on the Prognosis of Transitional Cell
Carcinoma of the Upper Urinary Tract
This study aimed to investigate the relationship of caveolin-1 expression with prog-
nosis in patients with transitional cell carcinoma of the upper urinary tract (TCC-
UUT). Formalin-fixed, paraffin-embedded tissue sections of TCC-UUT from 98
patients, who had undergone radical nephroureterectomy, were stained immuno-
histochemically using antibodies against caveolin-1. The expression pattern of cave-
olin-1 was compared with the clinicopathological variables. The caveolin-1 expres-
sion was significantly correlated with T stage (p<0.001) and grade (p=0.036). The
survival rate of patients with caveolin-1 positive tumors was significantly lower than
that of patients with caveolin-1 negative tumors (p<0.0001). The univariate analy-
ses identified T stage, grade, and caveolin-1 expression as significant prognostic
factors for cancer-specific survival, whereas the multivariate analyses indicated that
T stage and caveolin-1 expression were independent prognostic factors. These
results show that the increased expression of caveolin-1 is associated with tumor
progression and poor prognosis in TCC-UUT, suggesting that caveolin-1 may play
an important role in the progression of TCC-UUT.
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22 women; mean age of 61.7 yr, range 33-85 yr), who had
been diagnosed with TCC-UUT, were assessed. All patients
had undergone radical nephroureterectomy either at Ajou
University Hospital or Yonsei Medical Center between Novem-
ber 1994 and December 2004. Tumors were staged using
the 2002 TNM staging system (18) and graded according
to the World Health Organization (WHO)/International
Society of Urological Pathology (ISUP) grading criteria (19).
Immunohistochemistry
Immunohistochemical staining for the expression of cave-
olin-1 was carried out as previously described (12). Briefly,
paraffin-embedded 4- m tissue sections were deparaffinized,
treated with 3% hydrogen peroxide, followed by incubation
with the blocking reagent, and then incubated with mouse
monoclonal antibody against caveolin-1 (clone 2297, dilut-
ed 1:200; BD Biosciences, San Diego, CA, U.S.A.) for 1 hr
at 37℃. Staining was carried out by the standard streptavidin-
biotin-peroxidase complex method. Positive caveolin-1 stain-
ing of smooth muscle cells or endothelium, known to be
abundant in caveolin-1, served as an internal positive con-
trol. Negative controls were obtained by omitting the pri-
mary antibody.
Evaluation of immunohistochemical staining
The immunostaining was independently evaluated by two
pathologists who were unaware of the clinical data. The cave-
olin-1 expression was based on the presence of cytoplasmic
and/or membranous staining, which was semi-quantitative-
ly estimated according to the methods described by Sinicrope
et al. (20), with minor modifications. On the basis of the per-
centages of immunopositive cells, the data were subdivided
into five categories: 0, ≤10%; 1, 11-25%; 2, 26-50%; 3,
51-75%; and 4, >75% positive cells. The immunointensity
was also subclassified into four categories: 0, negative; 1, weak;
2, moderate (same intensity of smooth muscle cells); and 3,
strong (Fig. 1). The immunoreactive score (caveolin-1 expres-
sion) for each case was generated by multiplying the values
for the two parameters. A score of 0 was considered as nega-
tive, while all other scores were considered as positive.
Fig. 1. Immunohistochemical staining for caveolin-1. (A) Cancer cells were not stained (caveolin-1 intensity 0). (B) Smooth muscle cells
were stained as an internal control. Cancer cells were weakly stained, compared to an internal control (caveolin-1 intensity 1). (C) Cancer
cells were stained in same intensity as internal control (caveolin-1 intensity 2). (D) Cytoplasms of cancer cells were strongly stained for
caveolin-1 (caveolin-1 intensity 3). Original magnification, ×400.
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Statistical analysis
The correlation between caveolin-1 expression and various
clinicopathological variables was analyzed by the chi-square
test. The cancer-specific survival calculations were illustrat-
ed with Kaplan-Meier curves, and univariate and multivari-
ate analyses were performed using the log-rank test and the
Cox proportional hazards regression model, respectively. The
values of p<0.05 were considered to be statistically signifi-
cant in all of the analyses. All statistical analyses were per-
formed using SPSS
�, version 12.0.
RESULTS
The clinicopathological characteristics of the 98 patients
with TCC-UUT are summarized in Table 1. There were no
distant metastases in any patients at the time of radical neph-
roureterectomy. Seventy patients were disease-free at a medi-
an follow-up of 52.5 months (range, 12-162 months). The
other 28 patients developed metastases at a median of 28
months (range, 4-86 months) after radical nephroureterec-
tomy. Twenty-seven patients died of disease during the fol-
low-up period.
The patterns of caveolin-1 expression in the 98 patients are
summarized in Table 2. Of the 98 sections, positive immunos-
taining for caveolin-1 was observed in 10 sections (10.2%).
The caveolin-1 expression was significantly correlated with
T stage (p<0.001) and grade (p=0.036), but not with N stage
(p=0.149), tumor location (p=0.847), previous history of blad-
der cancer (p=0.711), coexisting bladder cancer at diagnosis
(p=0.211), or bladder cancer recurrence during the follow-
Characteristics No. of patients (%)
T stage
Ta 8 (8.2)
T1 56 (57.1)
T2 9 (9.2)
T3 21 (21.4)
T4 4 (4.1)
N stage
N0 90 (91.8)
N1 5 (5.1)
N2 3 (3.1)
Grade
Low 40 (40.8)
High 58 (59.2)
Tumor location
Renal pelvis 56 (57.1)
Ureter 42 (42.9)
Previous history of bladder cancer
No 91 (92.9)
Yes 7 (7.1)
Coexisting bladder cancer
No 89 (90.8)
Yes 9 (9.2)
Bladder cancer recurrence
No 63 (64.3)
Yes 35 (35.7)
Table 1. Clinicopathological data of the 98 patients included in
the study Variables
No. of
patients (%)
p
value
No. of caveolin-1
positive tumors (%)
T stage
Superficial (Ta+T1) 64 (65.3) 1 (1.6) <0.001
Invasive (T2-T4) 34 (34.7) 9 (26.5)
N stage
N0 90 (91.8) 8 (8.9) 0.149
N1+N2 8 (8.2) 2 (25.0)
Grade
Low 40 (40.8) 1 (2.5) 0.036
High 58 (59.2) 9 (15.5)
Tumor location
Renal pelvis 56 (57.1) 6 (10.7) 0.847
Ureter 42 (42.9) 4 (9.5)
Previous history of bladder cancer
No 91 (92.9) 9 (9.9) 0.711
Yes 7 (7.1) 1 (14.3)
Coexisting bladder cancer
No 89 (90.8) 8 (9.0) 0.211
Yes 9 (9.2) 2 (22.2)
Bladder cancer recurrence
No 63 (64.3) 7 (11.1) 0.691
Yes 35 (35.7) 3 (8.6)
Table 3. Relationship between caveolin-1 expression and clini-
copathological variables
Intensity Total
Proportion
01 2 3 4
08 6 0 0 0 0 8 6
12 4 1 0 0 7
20 1 0 1 0 2
30 1 2 0 0 3
Total 88 6 3 1 0 98
Table 2. Pattern of caveolin-1 expression in the 98 patients
Variables
Univariate
p value
Multivariate
p value Hazards ratio (95% CI)
T stage <0.0001 3.068 (1.078-8.736) 0.036
N stage 0.0682 1.398 (0.402-4.861) 0.598
Grade 0.0172 1.315 (0.446-3.871) 0.620
Tumor location 0.8689 1.415 (0.574-3.491) 0.451
Previous history of  0.3393 0.793 (0.175-3.600) 0.764
bladder cancer
Coexisting bladder cancer 0.7997 0.812 (0.204-3.235) 0.767
Bladder cancer recurrence 0.3694 1.594 (0.701-3.625) 0.266
Caveolin-1 expression <0.0001 5.080 (1.799-14.342) 0.002
Table 4. Univariate and multivariate survival analyses
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up (p=0.691) (Table 3).
A Kaplan-Meier survival curve showed that the survival
rate of patients with caveolin-1 positive tumors was signifi-
cantly lower than that of patients with caveolin-1 negative
tumors (p<0.0001) (Fig. 2).
The univariate analyses identified T stage (p<0.0001), grade
(p=0.0172), and caveolin-1 expression (p<0.0001) as signif-
icant prognostic factors for cancer-specific survival, whereas
the multivariate analyses indicated that T stage (p=0.036)
and caveolin-1 expression (p=0.002) were independent prog-
nostic factors (Table 4).
DISCUSSION
The role of caveolin-1 in cancers still remains controver-
sial. Several studies have suggested that caveolin-1 could func-
tion as a tumor suppressor gene. The genes encoding cave-
olin-1 and -2 are localized at the D7S522 locus located on
human chromosome 7q31.1, a region frequently deleted in
various types of human cancers (21). The allelic loss at chro-
mosome 7q31.3 occurred in all grades and stages of invasive
ovarian carcinomas, but not in borderline ovarian tumors,
suggesting that the inactivation of a tumor suppressor gene
in this region is an early event in ovarian tumorigenesis (22).
Caveolin-1 (-/-) null mice showed acceleration of the devel-
opment of dysplastic mammary lesions (23), and caveolin-1
transfected human breast cancer cell line MCF-7 cells showed
less proliferation than the vector control transfectants (11).
In addition, the caveolin-1 expression has been found to be
down-regulated in ovarian carcinoma, pulmonary adenocar-
cinoma, and sarcomas (8-10). Taken together, these findings
suggest that caveolin-1 has tumor suppressor characteristics.
In contrast, however, several studies have shown elevated
caveolin-1 expression levels in some cancers and cancer cell
lines. The increased expression of caveolin-1 has been found
to be associated with drug-resistant cancer cell lines, such as
paclitaxel or etoposide-resistant human lung cancer cells and
androgen-insensitive mouse prostate cancer cells (24-26). Fur-
thermore, the increased caveolin-1 expression has been report-
ed in renal cell carcinoma, prostate cancer, bladder cancer,
colonic carcinoma, and esophageal squamous cell carcinoma.
In many of these tumors, caveolin-1 overexpression was asso-
ciated with higher tumor stage, tumor invasion, tumor size,
higher grade, and poor prognosis (12-17). These findings
indicate that caveolin-1 may function as a tumor promoter
during carcinogenesis rather than as a tumor suppressor.
The differential expression of caveolin-1, depending on the
histologic subtypes of cancers or different malignant stages,
has also been reported. In the majority of small cell lung can-
cers, caveolin-1 expression was lost through promoter methy-
lation, the major mode of inactivation of many tumor sup-
pressor genes in human cancers, whereas caveolin-1 expres-
sion in the majority of non-small cell lung cancers was retain-
ed and appeared to be required for tumor growth through
the activation of FAK and Ra1A signaling (27). In lung ade-
nocarcinomas, the caveolin-1 served as a tumor suppressor
with the loss of caveolin-1 regulation, resulting in tumor
extension and dedifferentiation, whereas caveolin-1 overex-
pression in lung squamous cell carcinoma was correlated with
tumor extension, suggesting that these reciprocal functions
of caveolin-1 are due to different activation states of the dif-
ferent domains of caveolin-1 and altered interactions with
binding partners (28). In oral squamous cell carcinomas, the
rate of caveolin-1 immunoreactivity increased progressively
from normal oral mucosa, oral pre-cancer lesions to primary
carcinomas, whereas it decreased from primary to metastatic
carcinomas. These findings indicated the possibility of bipha-
sic behavior of caveolin-1 in oral carcinogenesis and metas-
tasis (29). Therefore, caveolin-1 might function either as a
tumor promoter or as a tumor suppressor, depending on the
tumor cell types or malignant stages.
For the expression of caveolin-1 in urothelial carcinomas,
studies have been done in bladder carcinomas, but not in
TCC-UUT. Rajjayabun et al. (14) found that the caveolin-1
expression was correlated with tumor stage and grade of blad-
der TCC, but not with tumor multiplicity, recurrence, pro-
gression, or survival of patients. Positive immunostaining for
caveolin-1 was detected in 10.1% of tumor specimens. Fong
et al. (15) showed that positive caveolin-1 immunostaining
was detected in 37% of urothelial carcinoma, but not in
nonneoplastic urothelium, and that the elevated expression
of caveolin-1 and -2 was correlated with tumor grade and
squamous differentiation.
In the present study, we investigated the expression of cave-
olin-1 in TCC-UUT and found that the positive immunos-
taining for caveolin-1 was observed in 10.2% of sections, sim-
ilar to the findings of Rajjayabun et al. (14) in bladder TCC.
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Fig. 2. Kaplan-Meier cancer-specific survival curves according to
the caveolin-1 expression. The survival rate of patients with cave-
olin-1 positive tumors was significantly lower than that of patients
with caveolin-1 negative tumors (p<0.0001).
Caveolin-1 (+) (n=10)300 D.S. Cho, H. Yim, K.S. Cho, et al.
Furthermore, the caveolin-1 expression was correlated signif-
icantly with T stage and grade. The survival rate of patients
with caveolin-1 positive tumors was significantly lower than
that of patients with caveolin-1 negative tumors. Also, the
caveolin-1 expression was an independent prognostic factor
for cancer-specific survival. These findings strongly indicate
that caveolin-1 is involved in tumor progression, and that
the increased expression of caveolin-1 is a late event in urothe-
lial carcinomas.
In conclusion, the increased expression of caveolin-1 is asso-
ciated with tumor progression and poor prognosis in TCC-
UUT, suggesting that caveolin-1 may play an important role
in the progression of TCC-UUT.
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